Entos Pharmaceuticals Inc.
Lipid nanoparticle-based genetic medicine delivery platform using proprietary Fusogenix technology
- Sector
- Biotech
- Headquarters
- EDMONTON, A0
- Founded
- 2016
- Latest Form D
- $100K, May 2020
- Total capital
- $100K
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $100K
- 1 Form D · last May 2020
- 77 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 11 pending · first 2022
- Rank in peer group#38 of 342
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$100K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 342 peers
Line = medianBiotech · Platform
- Granted patents#38 · top 11%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Roy DuncanResearcherDirectorLinked by 3 patents
- John LewisResearcherExecutive OfficerLinked by 2 patents
- Andries ZijlstraDirectorNamed in SEC Form D filings
- Arun RaturiExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 16- GrantedRecombinant Polypeptides For Membrane Fusion And Uses ThereofUSPTOUS 12,454,557
- GrantedMethods For Diagnosing And Treating Metastatic CancerUSPTOUS 12,421,514
- GrantedRecombinant Oncolytic Viruses For Treatment Of Metastatic CancersUSPTOUS 12,378,289
Show all 16 patent records
- Recombinant Polypeptides For Membrane Fusion And Uses ThereofOct 28, 2025 · US 12,454,557Granted
- Methods For Diagnosing And Treating Metastatic CancerSep 23, 2025 · US 12,421,514Granted
- Recombinant Oncolytic Viruses For Treatment Of Metastatic CancersAug 5, 2025 · US 12,378,289Granted
- Sars COV-2 Vaccine, Associated Polynucleotides, And Methods Of UseMar 20, 2025 · Application 18713809Pending
- Sars COV-2 Vaccines, Associated Polynucleotides, And Methods Of UseDec 5, 2024 · Application 18678619Pending
- Proteolipid Vesicles Formulated With Fusion Associated Small Transmembrane ProteinsNov 14, 2024 · Application 18613605Pending
- Proteolipid Vesicles Formulated With Fusion Associated Small Transmembrane ProteinsJun 13, 2024 · Application 18029823Pending
- Dna Therapeutic Encoding An Antibody Or Antigen Binding FragmentMar 21, 2024 · Application 18303407Pending
- Recombinant Polypepties for Membrane Fusion and Uses ThereofOct 4, 2022 · US 11,459,362Granted
- Methods For Diagnosing And Treating Metastatic CancerFeb 1, 2022 · US 11,236,331Granted
- Dna Therapeutic Encoding An Antibody Or Antigen Binding FragmentApplication 63332386Pending
- Dna Therapeutic Encoding An Antibody Or Antigen Binding FragmentApplication 63347120Pending
- Sars COV-2 Vaccine, Associated Polynucleotides, And Methods Of UseApplication 63264649Pending
- Sars COV-2 Vaccine, Associated Polynucleotides, And Methods Of UseApplication 63348260Pending
- Dna Therapeutic Encoding An Antibody Or Antigen Binding FragmentApplication 63357953Pending
- Sars COV-2 Vaccine, Associated Polynucleotides, And Methods Of UseApplication 63505368Pending
Related companies, and why
- PharmassetX Inc.Similar federal contract value in Biotech · null in contracts
- J2 Bio-Pharma, LLCSimilar federal contract value in Biotech · null in contracts
- Mimerigen, Inc.Similar federal contract value in Biotech · null in contracts
- Onramp BioInformatics, Inc.Similar federal contract value in Biotech · null in contracts
- Pierogi Therapeutics, IncSimilar federal contract value in Biotech · null in contracts
- BrainTrust BIO Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .